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VEGF as a Predictor for Response to Definitive 
Chemoradiotherapy and COX-2 as a Prognosticator for Survival 
in Esophageal Squamous Cell Carcinoma
We investigated the patterns of pretreatment expression of the epidermal growth factor 
receptor (EGFR), vascular endothelial growth factor (VEGF), and cyclooxygenase-2 (COX-2) 
by immunohistochemical staining and determined their correlation with treatment 
response and survival in 44 patients with esophageal squamous cell carcinoma (ESCC) 
treated with definitive concurrent chemoradiotherapy (CCRT). The definitive CCRT 
consisted of a median dose of 54 Gy (range: 40.0-68.4 Gy) and two cycles of concurrent 
administration of mostly 5-fluorouracil + cisplatinum. High expression of EGFR, VEGF, and 
COX-2 was found in 79.5%, 31.8%, and 38.6%, respectively. The Cox regression analysis 
for overall survival (OS) showed that both the treatment response and COX-2 expression 
were significant. The 3-yr OS rates of patients that achieved a complete response and 
those that did not were 46.7% and 5.3%, respectively (P = 0.006). The logistic regression 
analysis for treatment response with various parameters showed that only a high expression 
of VEGF was significantly associated with a complete response. Unlike other well-known 
studies, higher expression of VEGF was significantly correlated with a complete response to 
CCRT in this study. However, higher expression of COX-2 was significantly associated with 
shorter survival. These results suggest that VEGF might be a predictive factor for treatment 
response and COX-2 a prognostic factor for OS in patients with ESCC after definitive CCRT. 
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
The majority of patients with esophageal squamous cell carcino-
ma (ESCC) are diagnosed as having advanced disease with re-
gional or distant metastasis at the time of presentation; the 5-yr 
survival rate for these patients is still below 25% (1). The main 
treatment modality currently used is concurrent chemoradio-
therapy (CCRT) in patients with unresectable disease and the 
survival outcomes for this combined modality are much better 
than for radiotherapy alone (2, 3). However, local failure rates 
after CCRT are still as high as 45%-60% and improved local con-
trol is urgently needed (2, 3). Recent phase III European studies 
of preoperative CCRT, with or without surgery, in pati  ents with 
ESCC have shown that adding surgery to CCRT resulted in im-
provement of locoregional control compared to continuation of 
CCRT; however, the overall survival rates were similar (4, 5). A 
German study demonstrated that good responders to induction 
treatment had a better survival rate, regardless of the treatment 
group, whereas nonresponders generally had a shorter survival (4). 
  In patients with persistent or residual disease, the survival 
improved after receiving complete resection. However, the treat-
ment-related mortality was 9%-13% in the surgery group com-
pared to 1%-4% in the CCRT group. Therefore, pretreatment eval-
uation should be undertaken to predict which patients are likely 
to have a complete response to CCRT, or in whom surgery should 
be added due to an incomplete response. 
  Various factors have been evaluated as possible predictive or 
prognostic factors of esophageal cancer outcome; however, the 
data is conflicting and continues to be debated (6). In the pres-
ent study, three potential factors, namely, the epidermal growth 
factor receptor (EGFR), vascular endothelial growth factor 
(VEGF), and cyclooxygenase-2 (COX-2) were selected for eval-
uation. The expressions of EGFR has been reported to be asso-
ciated with better treatment response after CCRT (7) but poor 
treatment outcomes after primary surgery (8). VEGF is known 
to play a key role in tumor angiogenesis. It has been known that 
VEGF expression in esophageal carcinoma was associated with 
more advanced stage or poor prognosis (9, 10). Elevated COX-2 
expression is associated with resistance to treatment and reduced 
overall survival for patients who received CCRT (11). We performed 
retrospective analysis of the expression patterns of EGFR, VEGF 
and COX-2 in pretreatment endoscopic biopsy specimens by Yoon MS, et al.  •  VEGF and COX-2 in ESCC Patients Treated with CCRT   
514   http://jkms.org DOI: 10.3346/jkms.2011.26.4.513
immunohistochemical staining. The findings were assessed in 
an attempt to identify their predictive association with the treat-
ment response and survival. 
MATERIALS AND METHODS
Patient characteristics
From February 2001 to May 2008, a total of 44 patients with 
ESCC, that received definitive CCRT, without double primary 
lesions, were diagnosed as stage I-III according to the American 
Joint Committee on Cancer staging system with the 7th edition 
(12), and had endoscopic biopsy specimens pre- and post-treat-
ment available, were enrolled in the present study. To determine 
the stage, all patients underwent a thorough medical history, 
physical examination, complete blood cell count, serum bio-
chemistry, esophagography, upper gastrointestinal endoscopy 
with or without ultrasound, a computerized tomography (CT) 
of the chest and abdomen, and if necessary 
18F-fluorodeoxyglu-
cose-positron emission tomography. The clinical and tumor 
characteristics of the 44 patients are presented in Table 1. Most 
patients were male and all patients had squamous cell carcino-
ma. For 26 cases (59.1%), the primary tumors were located in 
the middle esophagus. Thirty-three (75.0%) primary lesions 
were staged as T3, and 31 (70.5%) as stage III. 
Radiotherapy 
Radiotherapy was performed using a LINAC 6- or 10-MV X-ray 
unit, in daily 1.8 or 2 Gy with five fractions per week. The radia-
tion dose ranged from 40 to 68.4 Gy with a median of 54 Gy. Ini-
tially anteroposterior and posteroanterior fields were used with 
a craniocaudal margin of 5 cm and a transverse margin of 2 cm 
adjacent to the gross tumor mass as determined by chest CT or 
esophagography. At doses between 36 and 40 Gy, a chest CT 
was performed for 3D-conformal radiotherapy planning and a 
boost dose was delivered to clinical target volumes with a cra-
niocaudal margin of 3 cm and a transverse margin of 2 cm ad-
jacent to the gross tumor volumes. Further radiotherapy boosts 
were administered to cervical and supraclavicular lymph nodes 
depending on nodal size. 
Chemotherapy 
To patients with adequate bone marrow function, as well as he-
patic, and renal function, concurrent chemotherapy was deliv-
ered with 5-fluorouracil based regimen. Cisplatinum (75 mg/m
2) 
was administered intravenously on the first day of weeks 1, 5, 9, 
and 13, and 5-fluorouracil (1,000 mg/m
2) was administered as 
a continuous infusion for the first 4 days of weeks 1, 5, 9, and 13; 
the first two cycles were delivered concurrently with radiother-
apy. Thirty-one patients (70.5%) received cisplatinum + 5-fluo-
rouracil with a median of three cycles (range 1-10) and 13 pa-
tients received cispatinum plus TS-1 of oral fluorouracil agent. 
Immunohistochemical staining 
The biopsy specimens were all obtained via pretreatment en-
doscopy with one sample for each case. Specimens were rou-
tinely fixed in 10% buffered formalin and embedded in paraf-
fin. Five serial paraffin-embedded sections (4 μm-thick) were 
prepared for immunostaining. The sections were dewaxed us-
ing xylene, transferred to alcohol, then placed in citric acid buf-
fer (10 mM/L) and heated in a microwave oven (700 W) for 12 
min to expose the antigens. Endogenous peroxidase activity was 
blocked by incubating the sections with 3% hydrogen peroxide 
in methanol for 30 min; the slides were then washed three times 
in phosphate-buffered saline (PBS), incubated in 10% normal 
goat serum for 20 min to reduce nonspecific antibody binding, 
and washed with PBS. The slides were incubated overnight at 
4°C with the monoclonal antibodies, i.e., with the monoclonal 
antibody against EGFR (clone H11, diluted 1:200, Dako, Glos-
trup, Denmark), VEGF (clone VG1, diluted 1:50, Dako), and COX-
2 (clone CX-294, diluted 1:100, Dako). The samples were visual-
ized by the EnVision method (Dako) according to the manufac-
turer’s instructions. Lung squamous cell carcinoma strongly ex-
pressing EGFR, VEGF, and COX-2 was used as a positive control. 
For the negative control, sections were similarly treated but with-
out the primary antibody.
 
Evaluation of immunohistochemical staining
Each slide was examined under the same magnification (× 200, 
Table 1. Patient characteristics
Characteristics Patients (%)
Age (yr) 47-77 (median: 64)
Sex  Male:Female 43:1
ECOG PS*
   0-1
   2
 
37 (84.1)
  7 (15.9)
Tumor location 
   Upper
   Middle
   Lower
   Multiple
 
11 (25.0)
22 (50.0)
  7 (15.9)
4 (9.1)
Tumor length (cm)
   ≤ 6
   > 6
 
26 (59.1)
18 (40.9)
Stage 
   I
   II
   IIIA
   IIIB
   IIIC
 
3 (6.8)
10 (22.7)
15 (34.2)
  6 (13.6)
10 (22.7)
Radiation dose (Gy)
   ≤ 54
   > 54
 
28 (63.6)
16 (36.4)
Chemotherapy 
   5-FU + Cisplatin
   TS-1 + Cisplatin
 
31 (70.5)
13 (29.5)
ECOG PS, Performance score by Eastern Cooperative Oncology Group; 5-FU, 
5-fluorouracil; TS-1, Tegafur + Gimeracil + Oteracil. Yoon MS, et al.  •  VEGF and COX-2 in ESCC Patients Treated with CCRT  
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Vanox-S, Olympus, Tokyo, Japan) by one independent patholo-
gist who moved the microscope field randomly across the spec-
imens. For the assessment of EGFR, the immunoreactivity of 
EGFR was graded into four groups according to the intensity of 
cell membrane EGFR staining: high (markedly stronger stain-
ing than normal esophageal epithelium), medium (moderately 
stronger staining), low (the same staining level as normal epithe-
lium), and negative (fainter staining). Strong and moderate stain-
ing groups were defined as positive for EGFR expression (7). For 
the evaluation of VEGF expression, when intensive positive stain-
ing of VEGF was observed in more than 10% of the tumor cells, 
the case was considered VEGF-positive (10). For COX-2, the in-
tensity of staining was determined as 0 (negative), 1 (weak), 2 
(moderate), and 3 (strong). A combined score based on the stain-
ing intensity and the percentage of stained cells was used as the 
final score. Low expression was defined as an intensity of 2 or 3 
and < 10% stained cells or an intensity of 0 or 1 and < 50% stained 
cells. High expression was defined as an intensity of 2 or 3 and  
> 10% stained cells or intensity 1 and > 50% stained cells (13).
Evaluation of tumor response and statistical analysis 
To evaluate tumor responses, an endoscopic biopsy and a chest 
CT scan were performed within one month of completing radio-
therapy. Follow-up CT and esophagography were performed 
every three months for the first two years and every six months 
thereafter. A complete disappearance of the primary tumor and 
regional lymph nodes on radiologic study was defined as com-
plete response (CR) and otherwise as non-complete response 
(non-CR). Endoscopy and CT were repeated when new clinical 
symptoms were present. The chi-square test or Fisher’s exact 
test were used to compare frequencies. The survival rates were 
calculated using the Kaplan-Meier method and the log-rank test 
was used to compare the survival curves. Logistic regression 
analysis was performed to identify variables significantly asso-
ciated with the tumor response. The Cox proportional hazards 
model was used to identify variables related to overall survival 
(OS) and cause-specific survival (CSS). When calculating CSS, 
death of esophageal cancer was regarded as an event but that of 
unknown cause or other cause as a censored case. All statistical 
analyses were performed using SPSS 17.0 and P values less than 
0.05 was considered statistically significant.
Ethics statement
The study was approved by the institutional review board of 
Chonnam National University Hwasun Hospital (2010-75). In-
formed consent was exempted by the board because the study 
was retrospective. 
Fig. 1. Overall survival according to the treatment response and the patterns of protein expression: (A) The Kaplan-Meier survival curve shows a significant difference between 
the patients with a complete response (CR) and those without a complete response. (B, C) the survival analyses of EGFR (B) and VEGF (C) did not show significant differences. (D) 
The patients with a higher expression of COX-2 show a significantly lower overall survival. 
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RESULTS
Treatment response and survival outcomes 
The median follow-up for all patients was 16 months with a 
range of 3-48 months. At the end of this study, 32 out of the 44 
patients had died. Among the 32 dead patients, 17 patients died 
of progressive or recurrent disease of esophageal carcinoma. The 
remaining patients died of unknown causes were considered as 
a censored case on the cause-specific survival analysis. The me-
dian overall survival time for all 44 patients was 16 months, with 
a 3-yr overall survival rate (OSR) of 27.7% and a 3-yr cause-spe-
cific survival rate (CSSR) of 45.1%. The 3-yr OSRs for stages I, II, 
IIIA, IIIB, and IIIC were 66.7%, 20.0%, 33.3%, 50.0%, and 10.0%, 
respectively (P = 0.37), which lack of significance might be caus-
ed by small number of patients groups. The 3-yr CSSRs for stag-
es I, II, IIIA, IIIB, and IIIC were 100%, 40.0%, 55.5%, 62.5%, and 
17.5%, respectively (P = 0.04). Twenty-five patients (56.8%) achi-
eved a CR and the 3-yr OSRs of patients that achieved a CR and 
those that did not were 46.7% and 5.3%, respectively (P < 0.01) 
(Fig. 1A). The 3-yr CSSRs of patients with a CR and those with-
Table 2. Correlations between clinical/pathological characteristics and EGFR, VEGF, and COX-2 expression (chi-square test or Fisher’s exact test)  
Characteristics
EGFR
P value
VEGF
P value
COX-2
P value
Low High Low High Low High
ECOG PS*
   0-1
   2
 
6
3
 
31
4
 
0.14 24
6
 
13
1
 
0.40
 
21
6
 
16
1
 
0.22
Tumor length
   ≤ 6 cm
   > 6 cm
  
5
4
  
21
14
 
1.0 20
10
 
13
8
 
0.14
 
16
11
 
10
7
 
1.0
Stage
   I + II
   III
 
2
7
  
11
24
  
0.70
 
5
25
 
8
6
 
0.01
 
10
17
 
3
14
 
0.17
T-stage
   T1 + 2
   T3 + 4
 
1
8
 
5
30
 
1.0
 
2
28
 
4
10
 
0.07
 
5
22
 
1
16
 
0.38
N-stage
   N-
   N+
 
2
7
 
11
24
 
0.70
 
5
25
 
8
6
 
0.01
 
9
18
 
4
13 
 
0.49
Response
   CR
   Non-CR
 
5
4
 
20
15
 
1.0
 
14
16
 
11
3
 
< 0.05
 
16
11
 
9
8
 
0.68
*Performance score by Eastern Cooperative Oncology Group. CR, complete response.
Fig. 2. Immunohistochemical staining of high and low expression of COX-2 (A, D), EGFR (B, E), and VEGF (C, F). 
100 µm 60 µm 100 µm
100 µm 100 µm 100 µm
A
D
B
E
C
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out were 66.4% and 13.7%, respectively (P < 0.01). For the OS 
analysis with other clinical and therapeutic parameters, the 
Eastern Cooperative Oncology Group (ECOG) performance 
score (P = 0.06) and tumor length (P = 0.08) were marginally 
significant. 
Relationship between treatment response and expression 
of EGFR, VEGF, and COX-2
COX-2 immunoreactivity was characteristically cytoplasmic and 
granular (Fig. 2A). Weak expression of COX-2 was often observed 
in normal-appearing squamous epithelium adjacent to carci-
nomas. EGFR expression was mainly seen in the cell membrane 
of tumor cells (Fig. 2B). Normal appearing epithelium adjacent 
to the carcinoma showed a few strongly positive cells. VEGF ex-
pression was primarily detected in the cytoplasm or cell mem-
branes of the tumor cells (Fig. 2C). The vascular endothelial cells 
within the carcinomas were weakly stained. According to our 
scoring criteria, high COX-2, EGFR, and VEGF expression was 
found in 38.6%, 79.5%, and 31.8%, respectively (Fig. 2). The cor-
relation between the patterns of expression and clinical/patho-
logical factors is listed in Table 2. The patients with a higher stage 
(III vs I + II), presence of regional lymph node metastases (N+ 
vs N-), and incomplete response had significantly lower expres-
sion of VEGF. However, the expression of EGFR and COX-2 did 
not have any significant correlation with the clinical/pathologi-
cal parameters. The multiple logistic regression analysis for de-
termining predictive factors associated with the treatment re-
sponse with 12 covariates of age (< 65 yr old vs ≥ 65 yr), ECOG 
score (0-1 vs 2), stage (I + II vs III), tumor location (upper vs mid 
vs lower vs multiple), tumor length (≤ 6 cm vs > 6 cm), T- stage 
(T1 + 2 vs T3 + 4), N-stage (N- vs N+), radiation dose (≤ 54 Gy vs 
> 54 Gy), radiotherapy duration (≤ 40 days vs > 40 days), and the 
expression of EGFR, VEGF, and COX-2 showed that only a high 
expression of VEGF was significantly correlated with the prima-
ry CR for CCRT in patients with ESCC (Table 3).
Relationship between survival outcomes and expression 
of EGFR, VEGF, and COX-2
The 3-yr OS analyses according to EGFR expression did not show 
significant differences (high vs low = 27.5% vs 33.3%. P = 0.90, 
Fig. 1B). The 3-yr OS of patients according to VEGF expression 
showed no significant difference (high vs low = 31.3% vs 26.3%, 
P = 0.37, Fig. 1C). However the patients with high COX-2 expres-
sion survived significantly shorter than those of low expression 
(17.6% vs 34.5%, P = 0.03, Fig. 1D). The Cox regression analysis 
for OS with the above 12 covariates adding treatment response 
showed that both treatment response (P < 0.01) and COX-2 ex-
pression (P = 0.03) were significantly correlated with OS (Table 4). 
However, the 3-yr CSS analyses revealed that EGFR (high vs low 
= 42.8% vs 64.3%, P = 0.47), VEGF (high vs low = 50.0% vs 44.0%, 
P = 0.27), and COX-2 (high vs low = 48.8% vs 46.6%, P = 0.38) did 
not show significant survival differences. The Cox regression anal-
ysis for the CSS of the above thirteen covariates showed that 
only the treatment response was significant (Table 5).
Table 3. Logistic regression analysis with potential variables predicting compete res-
ponse to definitive chemoradiotherapy
Variables Univariate  
(P value)
Multivariate  
(P value, RR, 95% [CI])
Age (< 65 yr vs ≥ 65 yr) 0.270 n-s
ECOG Performance (0-1 vs 2) 0.443 n-s
Stage (I + II vs III) 0.282 n-s
T classification (1 + 2 vs 3 + 4) 0.213 n-s
N classification (negative vs positive) 0.081 n-s
Tumor location 
   (upper vs mid. vs lower vs multiple)
0.548 n-s
Tumor length (≤ 6 cm vs > 6 cm) 0.198 0.057, 4.248 (0.957-18.856)
Radiotherapy dose (≤ 54 Gy vs > 54 Gy) 0.186 n-s
Radiotherapy duration
   (≤ 40 days vs >40 days)
0.632 n-s
EGFR (low vs high) 1.000 n-s
VEGF (low vs high) 0.047 0.023, 0.141 (0.026-0.767)
COX-2 (low vs high) 0.680 n-s
RR, relative risk; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; 
n-s, statistically non-significant.
Table 4. Cox proportional hazards model with potential variables predicting overall survival (OS)
Variables   3-yr OS (%) Univariate (P value) Multivariate (P value, HR, 95% [CI])
Age (< 65 yr vs ≥ 65 yr)   29.6 vs 25.3 0.357 n-s
ECOG Performance (0-1 vs 2)   30.0 vs 14.3 0.061 n-s
Stage (I + II vs III)   26.9 vs 29.0 0.606 n-s
T classification (1 + 2 vs 3 + 4)   22.2 vs 27.6 0.443 n-s
N classification (negative vs positive)   26.9 vs 29.0 0.786 n-s
Tumor location (upper vs mid vs lower vs multiple)   36.4 vs 20.5 vs 42.9 vs 25.0 0.753 n-s
Tumor length (≤ 6 cm vs > 6 cm)   36.9 vs 14.8 0.085 n-s
Radiotherapy dose (≤ 54 Gy vs > 54 Gy)   33.2 vs 18.8 0.183 n-s
Radiotherapy duration (≤ 40 days vs > 40 days)   41.2 vs 18.5 0.184 n-s
Treatment response (CR vs non-CR) 46.7 vs 5.3 0.006 0.006, 2.800 (1.338-5.858)
EGFR (low vs high)   33.3 vs 27.5 0.903 n-s
VEGF (low vs high)   26.3 vs 31.3 0.372 n-s
COX-2 (low vs high)   34.5 vs 17.6 0.030 0.025, 2.336 (1.112-4.908)
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; n-s, statistically non-significant; CR, complete response.Yoon MS, et al.  •  VEGF and COX-2 in ESCC Patients Treated with CCRT   
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DISCUSSION
VEGF is a potential biomarker for the prediction of treatment 
outcome in patients with esophageal cancer undergoing CCRT 
(14) or surgery (9, 15). Shih et al. (15) examined the relationship 
between VEGF expression, microvessel density (MVD), and clin-
ical/pathological factors in 117 patients with ESCC undergoing 
surgery. They demonstrated that survival of patients with VEGF-
positive tumors was significantly decreased compared to the 
patients with VEGF-negative tumors. A similar tendency for sur-
vival was observed for high-MVD versus low-MVD cases (32% 
vs 60%, P = 0.009). The MVD of the VEGF (+) tumors was higher 
than the VEGF (-) tumors; however, the difference was not sig-
nificant (P = 0.08). In a recent study reported by Shimada et al. 
(14), high pretreatment VEGF expression was associated with a 
poor response to CCRT and poor survival in patients with ESSC. 
The response rate of VEGF (+) tumors was significantly lower 
than VEGF (-) tumors (43% vs 90%, P < 0.001) and the multivar-
iate analysis identified VEGF as a significant independent prog-
nostic factor. However, other studies could not show an associ-
ation between VEGF expression and survival in patients with 
esophageal cancer undergoing surgery (16) or CCRT (17, 18).
  The results of this study showed that high VEGF expression 
was significantly correlated with a complete response to CCRT 
in ESCC. However, no prior study has demonstrated that higher 
VEGF expression is correlated with better responsiveness to 
CCRT in patients with esophageal cancer so far. The biological 
mechanism by which a high VEGF expression could result in 
improved response to CCRT remains unknown. Hypoxia in tu-
mors is an important factor associated radioresistance; it can 
also decrease the efficacy of chemotherapeutic agents due to 
alterations in blood flow and drug diffusion distance. Oxygen-
ation and drug delivery to cancer cells depends mostly on mi-
crovessels and blood flow in the tumor microcirculation. Most 
tumors have hypoxic areas that could drive VEGF production. 
VEGF has been shown to be the most important pro-angiogen-
ic factor involved in tumor growth (19, 20). Oxygenation and 
drug delivery might be more effective in tumors with high VEGF 
expression if VEGF was responsible for the hypervascularization 
of tumors. The destruction of tumor vessels, by anti-angiogenic 
agents, has been shown to increase tumor hypoxia, resulting in 
radioresistance. Indeed, some preclinical studies have shown 
that prolonged use of anti-VEGF agents has resulted in decreased 
MVD, and induced hypoxia, which would make radiation less 
effective (21, 22). Hironaka et al. (17) analyzed the prognostic 
factors including the clinical/pathological factors and biologi-
cal markers in pretreatment biopsy specimens from 73 patients 
with ESCC treated with definitive CCRT. They reported that the 
patients with a high MVD had significantly better survival than 
those with low MVD tumors. They suggested that the MVD was 
a favorable prognostic factor in patients undergoing CCRT be-
cause oxygenation and drug delivery could be enhanced in richly 
vascularized tumors. The association between VEGF expression 
and MVD is currently an active focus of research. For esophageal 
cancer, some studies have found a significant correlation be-
tween VEGF expression and MVD (10, 23), whereas others have 
not (15, 17). This discrepancy might be explained by interobserv-
er variation, the markers used, and the techniques; although the 
MVD has been widely used to quantify intratumor angiogenesis 
in human tumors (24). Hironaka et al. (17) assessed the MVD by 
counting intratumor and stromal vessels with the actual lumens 
around the tumor nests for consideration of tumor oxidation, 
instead of single endothelial cells and vessels far from the tumor 
nests. Although MVD was not evaluated in this study, the high 
VEGF expression might be correlated with high MVD of the tu-
mor, which could enhance the supply of oxygen and radiosen-
sitizing agents to cancer cells. Based on this postulation, we sug-
gest that high VEGF expression could be associated with more 
improved response to CCRT. Additional study is needed to deter-
mine whether the tumor with higher VEGF expression and dens-
er microvessel distribution could show better response to CCRT.
  VEGF increases vessel permeability, which subsequently leads 
Table 5. Cox proportional hazards model with potential variables predicting cause-specific survival (CSS)
Variables 3-yr CSS (%) Univariate (P value) Multivariate (P value, HR, 95% [CI])
Age (< 65 yr vs ≥ 65 yr) 43.1 vs 49.1 0.995 n-s
ECOG Performance (0-1 vs 2) 45.2 vs 37.5 0.859 n-s
Stage (I + II vs III) 50.0 vs 45.0 0.177 n-s
T classification (1 + 2 vs 3 + 4) 33.3 vs 45.1 0.499 n-s
N classification (negative vs positive) 43.7 vs 48.9 0.526 n-s
Tumor location (upper vs mid. vs lower vs multiple) 51.4 vs 38.2 vs 68.6 vs 33.3 0.841 n-s
Tumor length (≤ 6 cm vs > 6 cm) 52.9 vs 32.7 0.291 n-s
Radiotherapy dose (≤ 54 Gy vs > 54 Gy) 43.6 vs 52.4 0.932 n-s
Radiotherapy duration (≤ 40 days vs > 40 days) 54.1 vs 38.0 0.310 n-s
Treatment response (CR vs non-CR) 66.4 vs 13.7 0.003 0.011, 3.925 (1.375-11.207)
EGFR (low vs high) 64.3 vs 42.8 0.467 n-s
VEGF (low vs high) 44.0 vs 50.0 0.274 n-s
COX-2 (low vs high) 46.6 vs 48.8 0.383 n-s
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; n-s, statistically non-significant; CR, complete response.Yoon MS, et al.  •  VEGF and COX-2 in ESCC Patients Treated with CCRT  
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to the migration and organization of endothelial and tumor cells 
and promotes cancer cell invasion into the circulation (20). There-
fore, most studies have shown that VEGF is associated with the 
aggressive characteristics of ESCC. VEGF expression has been 
significantly correlated with the presence of lymph node me-
tastasis in patients with ESCC; VEGF expression was observed 
in 30%-49% of LN negative patients and 74%-87% of LN positive 
patients (9, 25, 26). Sato et al. showed that VEGF expression cor-
related with LN metastasis in patients with esophageal cancer; 
49% in the negative node group and 74% in the positive node 
group (25). Shih et al. (15) also showed that the number of met-
astatic LNs was closely related to the expression of VEGF; the av-
erage number of metastatic LNs at surgery was 5.6 in the VEGF-
positive cases and 3.0 in the VEGF-negative cases (P = 0.04). 
Some investigators have found that a high VEGF level was sig-
nificantly associated with advanced stage disease and a high 
frequency of distant metastases (9, 23), as well as a poorer sur-
vival (14, 15). The results of this study showed that the OSR and 
CSSR of patients with higher VEGF expression were not signifi-
cantly different from patients with lower VEGF expression. Al-
though higher VEGF expression was related with better treat-
ment response in this study, this phenomenon might be a tem-
poral event which occurred at the time of or shortly after CCRT. It 
can be assumed that in the long run, the well-known nature of 
biological aggressiveness of VEGF expression would eventually 
undermine the prognosis of patient, despite initial good treat-
ment response. Nevertheless, further prospective studies are 
needed with a larger population of patients to determine accu-
rate survival outcomes. Some studies have reported no signifi-
cant association between VEGF expression and clinical/patho-
logical factors in patients with esophageal cancer (16, 17, 27). 
This study showed that a lower VEGF expression was signifi-
cantly associated with the presence of lymph node metastasis, 
not with the primary lesion, resulting in a higher overall stage. 
Sato et al. classified the LN metastasis of esophageal cancer into 
two groups of patients that had LN dissection, early (cancer cells 
< 50% of lymph node) and late (≥ 50%) stage, according to the 
space occupying rates of the cancer cells (25). The VEGF-posi-
tive staining decreased from 60.7% in the early stage to 33.1% in 
the late stage, suggesting that the expression of VEGF changes 
during the temporal process of LN metastasis. Thus, the patients 
with high VEGF expression in this study might have actually had 
earlier stage of lymph node metastases or clinically undetect-
able nodal disease. Meanwhile it could not be excluded that 
there might be also a potential limitation in view of staging ac-
curacy in this study. Around only one third of patients received 
endoscopic ultrasonography or 
18F-fluorodeoxyglucose-posi-
tron emission tomography at the time of initial workup.
  The multivariate analysis of 13 variables including the clinical/ 
pathological and EGFR, VEGF, and COX-2 factors showed that 
both the treatment response and COX-2 expression were signif-
icant prognostic factors for OS and only treatment response for 
CSS. Huang et al. (11) reported that the overexpression of COX-2 
was significantly associated with a poor response to CCRT and a 
poor OS as in our study. The exact mechanism behind COX-2 
influencing tumor sensitivity to CCRT remains unclear. However, 
apoptosis suppression might be one explanation. When there is a 
high level of COX-2 expression in ESCC, tumor cells may not be 
sensitive to the apoptosis signal, and abnormal proliferation would 
be the result (11). Gotoh et al. (7) reported that EGFR (+) was 
significantly correlated with a CR of the primary esophageal le-
sion to CCRT. However, EGFR did not show a significant corre-
lation with the treatment response nor survival in this study.   
  In conclusion, unlike other well known studies, higher expres-
sion of VEGF was significantly correlated with the complete re-
sponse to CCRT in this study, whereas higher COX-2 expression 
was correlated with poorer survival. Although further prospec-
tive studies are needed to determine the mechanism by which 
the VEGF expression status could influence the response to 
CCRT with a larger patients population, these results suggest 
that VEGF might be a predictive factor for treatment response 
and COX-2 a prognostic factor for OS in patients with ESCC after 
definitive CCRT.
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AUTHOR SUMMARY
VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as  
a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma
Mee Sun Yoon, Taek-Keun Nam, Ji-Shin Lee, Sang-Hee Cho, Ju-Young Song, Sung-Ja Ahn, Ik-Joo Chung, Jae-Uk Jeong,  
Woong-Ki Chung, and Byung-Sik Nah
The patients with esophageal squamous cell carcinoma can achieve good prognosis even without surgery if they have complete 
response after concurrent chemoradiotherapy. This study showed that higher expression of VEGF was significantly correlated with 
complete response after chemoradiotherapy. We postulated that a higher VEGF expression induces more vascularization of tumor 
tissues, and thereby improve the response to chemoradiotherapy. However, this result is different from the previous studies by 
other groups, which requires further prospective study. On the other hand, higher COX-2 expression is correlated with poorer 
prognosis, which is consistent with previous studies. As a whole, in the patients with esophageal squamous cell carcinoma after 
definitive chemoradiotherapy, the expression levels of VEGF and COX-2 might be used as a predictive factor for the treatment 
response and the prognostic factor for survival, respectively. 